[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574282":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":16,"studyPopulation":17,"armGroups":18,"interventions":23,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":44,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":11,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":11,"maxAge":11,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":11,"briefSummary":16,"conditions":57,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Kissei Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Adverse events",null,"18 months",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","PROSPECTIVE","The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.","Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.",[19],{"label":20,"type":11,"description":11,"interventionNames":21},"fostamatinib treatmented",[22],"Drug: fostamatinib",[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","fostamatinib","oral administration",[20],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Kazunori Abe, director","CONTACT","0356843575","rinsyousiken@pharm.kissei.co.jp",[36],{"facility":37,"status":38,"city":39,"state":11,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":11,"geoPoint":11,"contacts":42},"Research site","RECRUITING","Tokyo and Japanese Other Cities","Japan","JP",[43],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100574282",false,"NCT06757257","Special Drug Use-results Survey for Long-term Use (Fostamatinib)","Inclusion Criteria:\n\n* Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.","ALL",{"count":53,"type":54},149,"ESTIMATED","18 Months","OBSERVATIONAL",[58],"Chronic Idiopathic Thrombocytopenic Purpura","2024-12-26",{"date":61,"type":62},"2025-01-03","ACTUAL",{"date":64,"type":62},"2023-05-29",{"date":66,"type":54},"2028-09-30",{"name":5,"class":6},1]